Oncorus, Inc. (NASDAQ:ONCR – Get Rating) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 852,400 shares, an increase of 20.7% from the October 31st total of 706,200 shares. Currently, 4.8% of the shares of the company are sold short. Based on an average daily volume of 77,100 shares, the days-to-cover ratio is presently 11.1 days.

Institutional Investors Weigh In On Oncorus

A number of institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new stake in Oncorus during the 2nd quarter worth approximately $476,000. Renaissance Technologies LLC grew its holdings in Oncorus by 23.9% during the 2nd quarter. Renaissance Technologies LLC now owns 217,450 shares of the company's stock worth $274,000 after acquiring an additional 41,918 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Oncorus by 106.6% during the 1st quarter. Bank of New York Mellon Corp now owns 122,047 shares of the company's stock worth $218,000 after acquiring an additional 62,985 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Oncorus by 35.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 117,925 shares of the company's stock worth $148,000 after purchasing an additional 30,668 shares during the period. Finally, Private Advisor Group LLC lifted its position in shares of Oncorus by 28.9% in the 2nd quarter. Private Advisor Group LLC now owns 81,304 shares of the company's stock worth $103,000 after purchasing an additional 18,220 shares during the period. 65.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ONCR has been the topic of several research reports. Piper Sandler downgraded shares of Oncorus from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $6.00 to $2.00 in a report on Wednesday. Chardan Capital downgraded shares of Oncorus from a "buy" rating to a "neutral" rating in a report on Wednesday.

Oncorus Price Performance

About Oncorus

(Get Rating)

Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.

Featured Articles

• Get a free copy of the StockNews.com research report on Oncorus (ONCR)
• Why CSL Ltd Stock Could Be Worth a Look
• MarketBeat: Week in Review 11/28 – 12/02
• Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
• Institutions Are Buying Ambarella, Should You?
• Can ZIM Defy Broad Downturn In The Container Shipping Industry?

Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.